All In Biotech

Drug Trial Radar · NCT03866174

A Study of Psilocybin for Major Depressive Disorder (MDD)

A Randomized, Double-Blind Study of Single-Dose Psilocybin for Major Depressive Disorder (MDD)

Last checked: Nov 19, 2026Latest source record: Apr 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 347 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

347

Actual

Start

Jan 23, 2020

Primary completion

Jun 28, 2022

Study completion Jun 28, 2022

Sponsor

Lead sponsor
Usona InstituteAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
The Emmes Company, LLC
First posted
Mar 7, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 21 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

One hundred participants, ages 21 to 65, who meet Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria for major depressive disorder (MDD) will be stratified by study site and randomized with a 1-to-1 allocation under double-blind conditions to receive a single 25 mg oral dose of psilocybin or a single 100 mg oral dose of niacin. Niacin will serve as an active placebo. The purpose of this study is to evaluate the potential efficacy of a single 25 mg oral dose of psilocybin for MDD compared to the active placebo in otherwise medically-healthy participants, assessed as the difference between groups in changes in depressive symptoms from Baseline to Day 43 post-dose.

Conditions

  • Depressive Disorder, Major

Interventions

  • PsilocybinDrug

    The psilocybin used in this study is synthetically manufactured in a laboratory and meets quality specifications suitable for human research use. The active drug is encapsulated using a hydroxypropyl methylcellulose (HPMC) capsule and contains 25 mg of psilocybin.

  • NiacinDrug

    The active placebo is encapsulated using a HPMC capsule and contains 100 mg of pharmaceutical grade niacin.

  • Set and Setting (SaS) ProtocolOther

    The SaS Protocol prescribes 6-8 hours of preparatory meetings with two facilitators prior to dosing, a 7-10 hour dosing session in a comfortable room under the supervision of the same two facilitators, and 4 hours of post-dose integration sessions with facilitators. During the dosing session participants are encouraged to wear eyeshades and listen to a curated playlist on headphones.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Central Rater Montgomery-Asberg Depression Rating Scale (MADRS) Total Score From Baseline to Post-dose Day 43Time frame: Baseline; Day 43 post-dose

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • University of California, San Francisco

    San Francisco, California

  • Pacific Neuroscience Institute

    Santa Monica, California

  • Yale University

    New Haven, Connecticut

  • Segal Trials

    Lauderhill, Florida

  • Emory University

    Atlanta, Georgia

  • Great Lakes Clinical Trials

    Chicago, Illinois

  • Johns Hopkins University

    Baltimore, Maryland

  • Hassman Research Institute

    Berlin, New Jersey

  • New York University School of Medicine

    New York, New York

  • Cedar Clinical Research

    Draper, Utah

  • University of Wisconsin - Madison

    Madison, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.